Collaborative R&D – a Catalyst of Innovation for Biopharmaceutical Companies

Date

Partagez l'article

Montreal, May 25, 2023 – Under BIOTECanada’s editorial direction, Insights Magazine is a goldmine of information about the global challenges and advancement of innovation in the biotech sector across Canada. In its most recent edition (page 78), our Director of Scientific Affairs, Fanny Guimont-Desrochers presents how collaborative R&D is a catalyst for innovation. She also highlights the success of CQDM\’s collaborative research projects with companies such as Defence Therapeutics, NMX Research and Solutions Inc., DalCor Pharmaceuticals and Pharmascience, as well as with multinationals like AstraZeneca and Bayer Inc.

To read the article or learn more, visit insights Magazine web page.

About CQDM

CQDM is a biopharmaceutical research consortium whose mission is to fund the development of innovative tools and technologies that will accelerate the discovery and development of safer and more effective drugs. We bring together world-leading pharmaceutical organizations, Canadian biotech companies, the best researchers from the public and private sectors, as well as the Canadian and Quebec governments. CQDM’s collaborative approach bridges the funding gap needed to drive innovation across the academic and private sectors, especially where early-stage research is concerned. For more information please visit: www.cqdm.org, and the CQDM’s pages on LinkedIn et Twitter.

For more information:

CQDM
info@cqdm.og

Scroll to Top